covid 19 News and Research

RSS

3-dose vaccines deemed ultrapotent against diverse and highly transmissible SARS-CoV-2 Omicron and other variants

A new study found that the presence of a subset of antibodies with broad neutralizing activities against all circulating variants of concern in the three-dose vaccines' memory B-derived antibody repertoire suggests that the Omicron/future variants infection may elicit selective and rapid recall of humoral responses, conferring secondary protection directed by memory etched in the immune system.

29 Dec 2021

Exploring immunogenicity and safety after a homologous booster dose of SARS-CoV-2 recombinant spike protein vaccine

Research suggests that a single booster dose of NVX-CoV2373 given approximately six months after the primary series induced significant increases in humoral antibodies, while also exhibiting an acceptable safety profile.

29 Dec 2021

Booster dose of mRNA vaccines found crucial in protecting against SARS-CoV-2 Omicron variants

A new study shows that Omicron is more infectious than any of the other variants and that booster vaccines, especially mRNA vaccines, are capable of neutralizing Omicron variants of pseudoviruses.

29 Dec 2021

New strategy to create a cheap and rapid COVID-19 test based on isothermal amplification

Russian researchers have developed a strategy to create a cheap and rapid COVID-19 test based on isothermal amplification. According to their publication in Applied Biochemistry and Microbiology, use of this strategy will make it possible to create universal test systems for any of the COVID-19 variants.

29 Dec 2021

Pregnant women should not delay COVID-19 vaccination until late pregnancy, study suggests

COVID-19 vaccination of expectant mothers elicits levels of antibodies to the SARS-CoV-2 outer "spike" protein at the time of delivery that don't vary dramatically with the timing of vaccination during pregnancy and thus don't justify delaying vaccination, according to a study from researchers at Weill Cornell Medicine and NewYork-Presbyterian.

28 Dec 2021

Estimating the epidemic potential of SARS-CoV-2 Omicron variant in South Korea

Researchers in South Korea and France have conducted an analysis on individuals infected with Omicron variant (B.1.1.529) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to estimate the epidemic potential and long-term prospects of this virus in circulation. They have found that the basic reproduction number (R0) for this variant is 1.90, while the mean serial interval is 2.22 days.

28 Dec 2021

Study demonstrates increased effectiveness of third BNT162b2 dose against SARS-CoV-2 infection and hospitalization

Researchers assess vaccine effectiveness of two and three doses of BNT162b2 against SARS-CoV-2 infections and COVID-19-related hospital admission.

28 Dec 2021

SARS-CoV-2 infection induces robust and cross-reactive immune responses in children

Researchers compare the convalescent humoral and cellular immune responses between children and adults infected with SARS-CoV-2.

28 Dec 2021

An evaluation of the association between COVID vaccination and myocarditis in 42 million people aged 13 or older

A new study posted to the medRxiv* pre-print server included individuals over 13 years of age receiving the third vaccine dose to further evaluate the association between myocarditis and COVID-19 vaccination or infection. The study took place from December 1, 2020, to November 15, 2021.

28 Dec 2021

SARS-CoV-2 Omicron variant neutralized by third BNT162b2 booster shot

A new preprint* research paper under consideration at Nature Portfolio Journal assesses the susceptibility of the Omicron variant to neutralizing antibody response after booster immunization.

28 Dec 2021

Pre-existing immunity against influenza can lower SARS-CoV-2 infection burden and spread

A recent study by a team of European researchers demonstrated how antibodies induced by currently circulating influenza A H1N1 strains can cross-react with the important part of the SARS-CoV-2 spike glycoprotein that interacts with the human cell receptor. Their paper is currently available on the medRxiv* preprint server while it undergoes peer review.

28 Dec 2021

Third BNT162b2 dose effectively neutralizes SARS-CoV-2 Omicron pseudovirus

The findings reveal that the Omicron neutralizing titers induced by the third vaccine dose are comparable to that achieved against the original Wuhan strain (wild-type SARS-CoV-2) by the two-dose regimen. The study is currently available on the medRxiv* preprint server while awaiting peer review.

28 Dec 2021

New report on 1.23 million breakthrough symptomatic SARS-CoV-2 infections by vaccine

A new research letter evaluates whether the estimated vaccine effectiveness changes against infection over time.

28 Dec 2021

Double-dose mRNA COVID vaccines effective among dialysis patients

Researchers assess the impact of lesser initial vaccine response and subsequent waning antibody levels on clinical outcomes among maintenance dialysis.

28 Dec 2021

Structural blueprint of nanoparticles developed to target neutrophils responsible for acute lung inflammation

The COVID-19 pandemic highlighted the devastating impact of acute lung inflammation (ALI), which is part of the acute respiratory distress syndrome (ARDS) that is the dominant cause of death in COVID-19.

28 Dec 2021

COVID isolation and quarantine period for general population shortened by CDC

Given what we currently know about COVID-19 and the Omicron variant, CDC is shortening the recommended time for isolation from 10 days for people with COVID-19 to 5 days, if asymptomatic, followed by 5 days of wearing a mask when around others.

27 Dec 2021

SARS-CoV-2-induced kidney damage

Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) infects the kidneys and contributes to tissue scarring, as shown by researchers from the RWTH Uniklinik Aachen, Germany, and Radboudumc, The Netherlands. The developed scar tissue in the infected kidneys may suggest a possible impact on kidney outcomes in the long term.

27 Dec 2021

covid 19 News and Research

3-dose vaccines deemed ultrapotent against diverse and highly transmissible SARS-CoV-2 Omicron and other variants

Exploring immunogenicity and safety after a homologous booster dose of SARS-CoV-2 recombinant spike protein vaccine

Booster dose of mRNA vaccines found crucial in protecting against SARS-CoV-2 Omicron variants

New strategy to create a cheap and rapid COVID-19 test based on isothermal amplification

Pregnant women should not delay COVID-19 vaccination until late pregnancy, study suggests

Estimating the epidemic potential of SARS-CoV-2 Omicron variant in South Korea

Study demonstrates increased effectiveness of third BNT162b2 dose against SARS-CoV-2 infection and hospitalization

SARS-CoV-2 infection induces robust and cross-reactive immune responses in children

An evaluation of the association between COVID vaccination and myocarditis in 42 million people aged 13 or older

SARS-CoV-2 Omicron variant neutralized by third BNT162b2 booster shot

Pre-existing immunity against influenza can lower SARS-CoV-2 infection burden and spread

Third BNT162b2 dose effectively neutralizes SARS-CoV-2 Omicron pseudovirus

New report on 1.23 million breakthrough symptomatic SARS-CoV-2 infections by vaccine

Double-dose mRNA COVID vaccines effective among dialysis patients

Structural blueprint of nanoparticles developed to target neutrophils responsible for acute lung inflammation

COVID isolation and quarantine period for general population shortened by CDC

SARS-CoV-2-induced kidney damage

APOE4 allele gene linked to increased risk of severe COVID-19

Uptake of COVID-19 vaccine doses increases before Christmas in England

UK Government to send out Get Boosted Now text messages from Boxing Day

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Exploring the G:Box and for high-quality imaging

Latest News